marked.bio

Company

RemeGen

7 active trials that select patients by a biomarker on marked.bio, across 4 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

disitamab vedotin 5toripalimab 3tislelizumab 1pyrotinib 1furmonertinib 1

Trials

7 of 13 trials shown

  1. A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Not yet recruiting Phase 3 RemeGen Started 2025Primary completion 2028-05 NCT06944496

    disitamab vedotintislelizumaboxaliplatincapecitabine

    HER2-low expression

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Gastric Carcinoma

  2. A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

    Not yet recruiting Phase 1/2 RemeGen Starts 2027Primary completion 2027-12 NCT05745740

    disitamab vedotinpyrotinib

    Documented HER2 exon 20 insertion mutation.

    HER2 (ERBB2) activating mutationNon-small Cell Lung Cancer

  3. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

    Recruiting Phase 2 RemeGen Started 2025Primary completion 2026-05 NCT06962865

    RC108furmonertinib

    Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  4. Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

    Recruiting Phase 2 RemeGen Started 2025Primary completion 2026-10 NCT06642545

    disitamab vedotinRC148Albumin-bound Paclitaxonetoripalimab

    Invasive breast tumor tissue has been confirmed as HER2 low expression by the central laboratory

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer

  5. To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

    Recruiting Phase 2 RemeGen Started 2024Primary completion 2025-06 NCT06389006

    disitamab vedotintoripalimabEpirubicincyclophosphamide

    Invasive breast tumor tissue with low HER2 expression confirmed by the central laboratory is defined as IHC 1+ or IHC 2+ expression of HER2 pro…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Status may be outdated, last updated 2024-05-23Breast Cancer

  6. Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

    Recruiting Phase 2 RemeGen Started 2023Primary completion 2025-12 NCT06227117

    disitamab vedotintoripalimabcarboplatinSequential Epirubicincyclophosphamide

    Invasive breast tumour tissue with low HER2 expression confirmed by the central laboratory, defined as HER2 protein expression of IHC 1+ or IHC …

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Status may be outdated, last updated 2024-03-19Breast Cancer

  7. A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

    Recruiting Phase 1/2 RemeGen Started 2022Primary completion 2025-09 NCT05205850

    RC118-ADC

    … junction cancer, pancreatic cancer, ovarian cancer, and cholangiocarcinoma with positive Claudin 18.2 expression (membrane staining is observed in any tumor cells)

    Claudin 18.2 expressionAdvanced Solid Tumor